We propose that the in-silico workflow used to successfully predict experimentally verified stabilized FGF21 mutants with uncompromised biological activity can be used in combination with other reported strategies to improve the potential of FGF21 as metabolic disease therapeutics. The gene discussed is FGF21; the disease is metabolic disease.